Home Cart Sign in  
Chemical Structure| 127-69-5 Chemical Structure| 127-69-5

Structure of Sulfisoxazole
CAS No.: 127-69-5

Chemical Structure| 127-69-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sulfisoxazole is an antagonist of endothelin receptor that can be used as a sulfonamide antibacterial agent.

Synonyms: Sulfafurazole; NSC 13120; Neoxazol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sulfisoxazole

CAS No. :127-69-5
Formula : C11H13N3O3S
M.W : 267.30
SMILES Code : O=S(C1=CC=C(N)C=C1)(NC2=C(C)C(C)=NO2)=O
Synonyms :
Sulfafurazole; NSC 13120; Neoxazol
MDL No. :MFCD00003150
InChI Key :NHUHCSRWZMLRLA-UHFFFAOYSA-N
Pubchem ID :5344

Safety of Sulfisoxazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Sulfisoxazole

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
4T1-CD63-GFP cells 100 µM 24 hours To evaluate the inhibitory effect of SFX on exosome release in 4T1-CD63-GFP cells, results showed SFX significantly reduced exosome secretion. Adv Sci (Weinh). 2025 Jan;12(2):e2406328
MDA-MB-231 breast cancer cells 50, 100 and 200 µM 24 hours To evaluate the effect of SFX on EV release, results showed SFX treatment did not reduce EV release Nat Commun. 2021 Feb 12;12(1):977
4T1 breast cancer cells 50, 100 and 200 µM 24 hours To evaluate the effect of SFX on EV release, results showed SFX treatment did not reduce EV release Nat Commun. 2021 Feb 12;12(1):977

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice MDA-MB231 xenograft model Oral 100-200 mg/kg/day Once daily for 14 days To evaluate the effect of SFX on circulating exosomal PD-L1 levels in MDA-MB231 xenograft models. Results showed SFX significantly reduced circulating exosomal PD-L1 levels. Adv Sci (Weinh). 2022 Feb;9(5):e2103245

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02099240 Osteomyelitis Early Phase 1 Recruiting September 2019 United States, Kentucky ... More >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.74mL

0.75mL

0.37mL

18.71mL

3.74mL

1.87mL

37.41mL

7.48mL

3.74mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories